国产中文无码av每日更新在线观看, 亚洲天堂中文字幕一区二区三区免费, 国产口爆吞精在线观视频-黄色国产, 92福利-国内精品久久久久久99,亚洲成AV人A片不卡无码,浪潮AV无码专区,老熟女败火白浆,中文字幕日产av,色情日本免费看大片

更新于 11月3日

Head of Int. Policy & Communications (IPC), China

20-23萬
  • 北京東城區(qū)
  • 10年以上
  • 本科
  • 全職
  • 招1人

雇員點(diǎn)評(píng)標(biāo)簽

  • 同事很nice
  • 團(tuán)隊(duì)執(zhí)行強(qiáng)
  • 工作環(huán)境好
  • 人際關(guān)系好
  • 氛圍活躍
  • 實(shí)力大公司

職位描述

藥企
Position Summary
The Head of International Policy & Communications (IPC), China, reports to the Senior Vice President for International Policy & Communications in New York City and serves on the Leadership Team for the President of Pfizer China. This role is responsible for leading a team to advance an integrated policy, public affairs, communications and patient advocacy strategy for Pfizer in China.
Responsibilities
Policy and Public Affairs
● Enhance visibility and give Pfizer a prominent voice with policymakers in China. Develop and maintain strong relationships with key China policy stakeholders to advance business goals and further develop Pfizer’s reputation as a credible and respected voice in the life science sector and on the impact of the China’s health environment on society and the economy.
● Lead a best-in-class Policy and Public Affairs team, with respect to performance, behaviours, skills, and talent management, preparing Pfizer for the future world and leading with our values.
● Maintain strict compliance with all applicable policies and laws, especially those related to interactions with government official.
● Advocacy and coalition building with industry associations and other stakeholders to support pro-innovation and patient-centric policies, including AmCham China, RDAC, PhRMA, USCBC China Office.
● Assess the impact of the dynamic policy environment on Pfizer’s business strategy and provide counsel in key business planning decisions such as the operating plan, business reviews, and business development work.
● Identify emerging policy and legislative trends relevant to healthcare and the pharmaceutical industry. Analyze the implications of these trends and provide recommendations to relevant Pfizer China and Global leaders.
● Build and maintain strong cross-functional relationships, including with global/regional policy teams (Market Access, Regulatory, etc.) to coordinate seamless, unified Pfizer representation to Chinese Government and ensure aligned Pfizer policy positions and strategy for engagement with Chinese authorities.
Communications (Internal/External)
● Proactively and reactively engage with media to build trust and reputation, positioning Pfizer as a leader in vaccines and oncology.
● Lead milestone communications (regulatory, data, clinical) for prioritized brands.
● Develop and execute public-facing disease awareness campaigns for prioritized disease areas and product categories.
● Manage external agencies for PR execution.
● Oversee social/digital communication platform management.
● Provide internal communications counsel for country leadership and develop narratives and materials to support colleague engagement initiatives.
Patient Advocacy
● Enhance the impact and quality of engagements with select patient advocacy groups.
● Capture and incorporate patient insights into Pfizer's decision-making processes.
Team Leadership
● Provide direct reports with clear and transparent roles and responsibilities.
● Create and maintain a team culture of integrity and compliance that values and drives high performance, supports innovation, and challenges the status quo.
● Encourage sharing of information and experiences to enhance productivity.
● Actively support development of direct reports and key talent by providing insights, direction, and opportunities.
● Win the right way by ensuring full compliance with local laws and regulations, as well as internal policies.
Qualifications
Professional Experience: 20+ years in the biopharmaceutical industry with experience in the fields of policy, government affairs, communications, and/or patient advocacy. BS/BA required, advanced degree preferred (MBA, MPH, JD).
Relationship Building: Proven track record of strong interpersonal abilities to cultivate and maintain relevant networks across government, key opinion leaders, media, industry, and the broader internal and external communities. Can successfully leverage these connections and network insights to positively amplify the company’s policy goals, advance its commercial interests, and strengthen Pfizer’s reputation.
Issue Management: Adept at anticipating and mitigating policy and political environmental risks. Can quickly identify emerging challenges and implement proactive strategies to navigate crises and turn them into opportunities. Agility and composure under pressure are hallmarks of success.
Strategic Thinking and Planning: Keen understanding of Pfizer’s broader objectives and the competitive landscape in China. Can align communications and policy engagement efforts across stakeholder groups to support the China commercial strategy, driving long-term value creation for the company.
Matrix Maturity: Dexterity to work between/across organizations and confidence to operate in a dotted and direct line matrix. Entrepreneurial mindset with a strong adherence to compliance and reputation management.
Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.
Public Affairs & Communication

工作地點(diǎn)

北京東城區(qū)五礦廣場-B座

職位發(fā)布者

王先生/區(qū)域招聘及入職交付

當(dāng)前在線
立即溝通
公司Logo輝瑞投資有限公司公司標(biāo)簽
輝瑞公司(Pfizer Inc.)創(chuàng)建于1849年,總部位于美國紐約,是一家以科學(xué)為基礎(chǔ)的、創(chuàng)新的、以患者為先的生物制藥公司。輝瑞的使命是“為患者帶來改變其生活的突破創(chuàng)新”。在輝瑞,我們通過科學(xué)和全球資源為人們提供治療方案,以延長其生命,顯著改善其生活。在醫(yī)療衛(wèi)生產(chǎn)品的探索、研發(fā)和生產(chǎn)過程中,輝瑞始終致力于奉行嚴(yán)格的質(zhì)量、安全和價(jià)值標(biāo)準(zhǔn)。我們?cè)谌虻漠a(chǎn)品組合包括創(chuàng)新藥品和疫苗。每天,輝瑞在發(fā)達(dá)和新興市場的員工都在推進(jìn)人類健康,推動(dòng)疾病的預(yù)防、治療和治愈,以應(yīng)對(duì)挑戰(zhàn)我們這個(gè)時(shí)代的頑疾。輝瑞還與醫(yī)療衛(wèi)生服務(wù)方、政府和社區(qū)合作,支持并促進(jìn)世界各地的人們能夠獲得更為可靠和可承付的醫(yī)療衛(wèi)生服務(wù)。這與輝瑞作為一家全球卓越的創(chuàng)新生物制藥公司的責(zé)任是一致的。170余年來,輝瑞一直致力于為所有依賴我們的人帶來改變。輝瑞于1989年進(jìn)入中國市場。扎根中國30余年,輝瑞已成為在華主要的外資制藥公司之一。2021年是輝瑞新征程的開始。迄今已有170余年歷史的輝瑞正在邁入全新時(shí)代,成為一家以科學(xué)為基礎(chǔ)的、創(chuàng)新的、以患者為先的生物制藥公司。目前輝瑞在中國業(yè)務(wù)覆蓋全國300余個(gè)城市,累計(jì)投資超過15億美元,并設(shè)立了1家先進(jìn)的生產(chǎn)設(shè)施,2個(gè)研發(fā)中心(分別位于上海張江高科技園區(qū)和武漢光谷),在華有近7,000名員工分布于業(yè)務(wù)、研發(fā)和生產(chǎn)等領(lǐng)域。輝瑞在華上市了五大領(lǐng)域的高品質(zhì)創(chuàng)新產(chǎn)品,包括腫瘤、疫苗、抗感染、炎癥與免疫、罕見病等多個(gè)領(lǐng)域的處方藥和疫苗,強(qiáng)大完善的產(chǎn)品線旨在滿足生命各階段的健康需求。
公司主頁